Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in enzyme therapy for Gaucher disease

G A Grabowski1

  • 1Division of Human Genetics, Children's Hospital Research Foundation, Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Drugs
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.

Molecular genetics and metabolism·2011
Same author

Genotype-phenotype correlations in Rubinstein-Taybi syndrome.

American journal of medical genetics. Part A·2008
Same author

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Journal of inherited metabolic disease·2008
Same author

Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.

Journal of cellular biochemistry·2008
Same author

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease.

Skeletal radiology·2007
Same author

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

Clinical genetics·2007

Enzyme replacement therapy has greatly improved Gaucher disease management, reversing key abnormalities in over 1200 patients. Further optimization requires standardized staging, better biochemical understanding, and cost-effective, safer enzyme preparations.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Enzyme replacement therapy (ERT) has revolutionized Gaucher disease management.
  • Studies involving over 1200 patients show significant improvements in hepatic, splenic, bony, and hematological abnormalities.
  • The therapy is generally well-tolerated, with adverse effects reported in approximately 7% of patients.

Purpose of the Study:

  • To review the impact of enzyme therapy on Gaucher disease.
  • To identify limitations and areas for improvement in current enzyme therapy protocols.
  • To provide insights for developing enzyme therapies for other inborn errors of metabolism.

Main Methods:

  • Review of clinical studies and patient data from over 1200 treated Gaucher disease patients.

Related Experiment Videos

  • Analysis of treatment outcomes, including regression of disease manifestations.
  • Assessment of safety and adverse effects associated with enzyme therapy.

    • Main Results:

    • Significant regression of hepatic, splenic, bony, and hematological abnormalities observed in treated patients.
    • Many patients experienced a return towards health.
    • Adverse effects were reported in about 7% of patients, indicating good tolerability.

    Conclusions:

    • Enzyme therapy is a highly effective treatment for Gaucher disease, offering significant clinical benefits.
    • Optimization requires standardized staging, improved understanding of enzyme biochemistry and cell biology, and development of safer, less expensive preparations.
    • Predictive genotype testing is crucial for optimizing preventive intervention.
    • Lessons learned from Gaucher disease ERT can guide the development of therapies for other metabolic disorders.